Skip to main content
SpringerLink
Log in

Rationale Behind Survivin Inhibition as a Potential Therapeutic Strategy in Head and Neck Carcinoma too

  • Letter to the Editor
  • Published:
Current Oncology Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Church DN, Talbot DC. Survivin in solid tumors: rationale for development of inhibitors. Curr Oncol Rep. 2012;14:120–8.

    Article  PubMed  CAS  Google Scholar 

  2. Nasr MR, El-Zammar O. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions. Am J Dermatopathol. 2008;30:117–22.

    Article  PubMed  Google Scholar 

  3. Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T, Tanigawa N. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res. 1998;58:5071–4.

    PubMed  CAS  Google Scholar 

  4. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917.

    Article  PubMed  CAS  Google Scholar 

  5. Marioni G, D'Alessandro E, Bertolin A, Staffieri A. Survivin multifaceted activity in head and neck carcinoma: current evidence and future therapeutic challenges. Acta Otolaryngol (Stockh). 2010;130:4–9.

    Article  Google Scholar 

  6. Lo Muzio L, Pannone G, Staibano S, et al. Survivin expression in oral squamous cell carcinoma. Br J Cancer. 2003;89:2244–8.

    Article  PubMed  CAS  Google Scholar 

  7. De Maria S, Pannone G, Bufo P, et al. Survivin gene-expression and splicing isoforms in oral squamous cell carcinoma. J Cancer Res Clin Oncol. 2009;135:107–16.

    Article  PubMed  CAS  Google Scholar 

  8. Preuss SF, Weinell A, Molitor M, et al. Nuclear survivin expression is associated with HPV-independent carcinogenesis and is an indicator of poor prognosis in oropharyngeal cancer. Br J Cancer. 2008;98:627–32.

    Article  PubMed  CAS  Google Scholar 

  9. Dong Y, Sui L, Watanabe Y, Sugimoto K, Tokuda M. Survivin expression in laryngeal squamous cell carcinomas and its prognostic implications. Anticancer Res. 2002;22:2377–83.

    PubMed  Google Scholar 

  10. Pizem J, Cör A, Gale N. Survivin expression is a negative prognostic marker in laryngeal squamous cell carcinoma and is associated with p53 accumulation. Histopathology. 2004;45:180–6.

    Article  PubMed  CAS  Google Scholar 

  11. Marioni G, Bertolin A, Giacomelli L, et al. Expression of the apoptosis inhibitor protein survivin in primary laryngeal carcinoma and cervical lymph node metastasis. Anticancer Res. 2006;26(5B):3813–7.

    PubMed  CAS  Google Scholar 

  12. Marioni G, Agostini M, Bedin C, et al. Survivin and laryngeal carcinoma prognosis: nuclear localization and expression of splice variants. Histopathology. 2012;61(2):247–56.

    Article  PubMed  Google Scholar 

  13. Eto M, Kodama S, Uemura N, Suzuki M. Antibody responses to survivin and their clinical significance in patients with head and neck cancer. Head Neck. 2007;29:1128–35.

    Article  PubMed  Google Scholar 

  14. Erpolat OP, Gocun PU, Akmansu M, Karakus E, Akyol G. High expression of nuclear survivin and Aurora B predicts poor overall survival in patients with head and neck squamous cell cancer. Strahlenther Onkol. 2012;188:248–54.

    Article  PubMed  CAS  Google Scholar 

  15. Bian K, Fan J, Zhang X, et al. MicroRNA-203 leads to G1 phase cell cycle arrest in laryngeal carcinoma cells by directly targeting survivin. FEBS Lett. 2012;586:804–9.

    Article  PubMed  CAS  Google Scholar 

  16. Miyazaki A, Kobayashi J, Torigoe T, et al. Phase I clinical trial of survivin-derived peptide vaccine therapy for patients with advanced or recurrent oral cancer. Cancer Sci. 2011;102:324–9.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurosciences, Otolaryngology Section, University of Padova, Via Giustiniani 2, 35128, Padova, Italy

    Gino Marioni

Authors
  1. Gino Marioni
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gino Marioni.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Marioni, G. Rationale Behind Survivin Inhibition as a Potential Therapeutic Strategy in Head and Neck Carcinoma too. Curr Oncol Rep 15, 1–2 (2013). https://doi.org/10.1007/s11912-012-0267-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-012-0267-3

Keywords

Search

Navigation